SCHEDULE 13G: Skylands Capital Discloses 5.1% Stake in CytoSorbents Corporation
Beneficial Ownership Report
Skylands Capital, LLC has reported a 5.1% beneficial ownership stake in CytoSorbents Corporation, holding 2,781,622 shares of common stock as of December 31, 2024.
Summary
- Skylands Capital, LLC, an investment adviser based in Milwaukee, Wisconsin, has filed a Schedule 13G indicating beneficial ownership in CytoSorbents Corporation.
- As of December 31, 2024, Skylands Capital, LLC beneficially owns 2,781,622 shares of CytoSorbents Corporation's Common Stock.
- This ownership represents 5.1% of the total outstanding class of securities.
- Skylands Capital, LLC holds sole voting power and sole dispositive power over all 2,781,622 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance metrics that would indicate a positive or negative sentiment regarding the company's operations or financial health.
Positives
- Skylands Capital, LLC, an investment adviser, has disclosed a significant beneficial ownership stake of 5.1% in CytoSorbents Corporation, holding 2,781,622 shares of common stock, which may be viewed as a vote of confidence by an institutional investor.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an institutional investor, common across all industries for publicly traded companies. It indicates an investment adviser's significant stake in a company within the biotechnology/medical device sector (CytoSorbents Corporation).
Stakeholder Impact
- Shareholders may perceive the disclosure of a significant stake by an investment adviser as a positive signal of institutional confidence in CytoSorbents Corporation.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires the filing of this statement (beneficial ownership calculation date). |
| 01/06/2025 | Date the Schedule 13G statement was signed by Virginia E. Shaffar, Vice President & Treasurer of Skylands Capital, LLC. |
Keywords
CytoSorbents Corporation, Skylands Capital, beneficial ownership, Schedule 13G, common stock, investment adviser, institutional ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.